NO20045245L - Anvendelse av valsartan eller dens metabolitt for a inhibere blodplateaggregering - Google Patents

Anvendelse av valsartan eller dens metabolitt for a inhibere blodplateaggregering

Info

Publication number
NO20045245L
NO20045245L NO20045245A NO20045245A NO20045245L NO 20045245 L NO20045245 L NO 20045245L NO 20045245 A NO20045245 A NO 20045245A NO 20045245 A NO20045245 A NO 20045245A NO 20045245 L NO20045245 L NO 20045245L
Authority
NO
Norway
Prior art keywords
metabolite
platelet aggregation
ischemic
valsartan
acute
Prior art date
Application number
NO20045245A
Other languages
English (en)
Norwegian (no)
Inventor
Randy Lee Webb
Victor L Serebruany
Alex Malinin
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29423705&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20045245(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20045245L publication Critical patent/NO20045245L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO20045245A 2002-05-14 2004-11-30 Anvendelse av valsartan eller dens metabolitt for a inhibere blodplateaggregering NO20045245L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38037302P 2002-05-14 2002-05-14
US39501402P 2002-07-11 2002-07-11
PCT/EP2003/004997 WO2003094915A1 (en) 2002-05-14 2003-05-13 Use of valsartan ot its metabolite to inhibit platelet aggregation

Publications (1)

Publication Number Publication Date
NO20045245L true NO20045245L (no) 2004-11-30

Family

ID=29423705

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20045245A NO20045245L (no) 2002-05-14 2004-11-30 Anvendelse av valsartan eller dens metabolitt for a inhibere blodplateaggregering

Country Status (22)

Country Link
US (2) US20050197372A1 (de)
EP (1) EP1505965B1 (de)
JP (1) JP4467427B2 (de)
KR (1) KR101005367B1 (de)
CN (1) CN100408035C (de)
AT (1) ATE334677T1 (de)
AU (1) AU2003267447B8 (de)
BR (1) BR0310018A (de)
CA (1) CA2482541A1 (de)
CY (1) CY1105638T1 (de)
DE (1) DE60307265T2 (de)
DK (1) DK1505965T3 (de)
ES (1) ES2268403T3 (de)
IL (2) IL164774A0 (de)
MX (1) MXPA04011282A (de)
NO (1) NO20045245L (de)
NZ (1) NZ536295A (de)
PL (1) PL371728A1 (de)
PT (1) PT1505965E (de)
RU (1) RU2334512C2 (de)
TW (1) TWI299663B (de)
WO (1) WO2003094915A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040265238A1 (en) * 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
WO2005030202A1 (en) * 2003-09-26 2005-04-07 Novartis Ag Use of angiotensin ii receptor antagonists for treating cerebrovascular disorders
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
AR068814A1 (es) * 2007-08-29 2009-12-09 Orion Corp Composicion farmaceutica que comprende levosimendan y un inhibidor de la enzima conversina de la angiotensina (ace), y uso
RU2410104C1 (ru) * 2009-07-10 2011-01-27 Учреждение Российской академии медицинских наук Научный центр неврологии РАМН СПОСОБ СНИЖЕНИЯ АГРЕГАЦИОННОЙ АКТИВНОСТИ ТРОМБОЦИТОВ in vitro
EP3096748B1 (de) 2014-01-24 2019-09-25 The Arizona Board of Regents on behalf of the University of Arizona Verfahren zur veränderung von scherkraft-induzierter blutplättchenaktivierung
CN110078640B (zh) * 2019-03-29 2022-04-05 浙江美诺华药物化学有限公司 一种缬沙坦中间体的合成方法
CN111643557B (zh) * 2020-05-26 2022-02-22 四川省骨科医院 一种防治下肢深静脉血栓后遗症期的药物组合物及其制备方法和用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08512198A (ja) * 1993-04-05 1996-12-24 ユニバーシティ・オブ・ユタ・リサーチ・ファウンデーション 大動脈弁上部狭窄およびウィリアムズ症候群の診断および治療
US6395728B2 (en) * 1999-07-08 2002-05-28 Novartis Ag Method of treatment and pharmaceutical composition
EP1197226B1 (de) * 1999-07-21 2007-11-21 Takeda Pharmaceutical Company Limited Mittel zur verbesserung der erkrankungen nach zerebralen durchblutungsstörungen sowie zur verhinderung deren fortschrittens
AU2001267404A1 (en) * 2000-05-04 2001-11-12 Ipf Pharmaceuticals Gmbh Novel compounds for the treatment of inflammatory and cardiovascular diseases
CZ20024180A3 (cs) * 2000-06-22 2003-04-16 Novartis Ag Pevné orální farmaceutické kompozice obsahující valsartan

Also Published As

Publication number Publication date
EP1505965B1 (de) 2006-08-02
EP1505965A1 (de) 2005-02-16
WO2003094915A1 (en) 2003-11-20
PT1505965E (pt) 2006-11-30
JP4467427B2 (ja) 2010-05-26
CA2482541A1 (en) 2003-11-20
DE60307265D1 (de) 2006-09-14
AU2003267447A1 (en) 2003-11-11
RU2334512C2 (ru) 2008-09-27
TWI299663B (en) 2008-08-11
KR101005367B1 (ko) 2010-12-30
BR0310018A (pt) 2005-02-15
CY1105638T1 (el) 2010-12-22
MXPA04011282A (es) 2005-01-25
CN100408035C (zh) 2008-08-06
KR20050000532A (ko) 2005-01-05
IL164774A (en) 2010-04-29
ATE334677T1 (de) 2006-08-15
NZ536295A (en) 2006-12-22
AU2003267447B2 (en) 2006-11-02
US20050197372A1 (en) 2005-09-08
IL164774A0 (en) 2005-12-18
DE60307265T2 (de) 2007-07-19
JP2005529913A (ja) 2005-10-06
TW200410686A (en) 2004-07-01
AU2003267447B8 (en) 2009-08-06
HK1074395A1 (en) 2005-11-11
ES2268403T3 (es) 2007-03-16
US20100048654A1 (en) 2010-02-25
DK1505965T3 (da) 2006-11-13
CN1652774A (zh) 2005-08-10
RU2004136583A (ru) 2005-09-10
PL371728A1 (en) 2005-06-27

Similar Documents

Publication Publication Date Title
Felker et al. Usefulness of anemia as a predictor of death and rehospitalization in patients with decompensated heart failure
Lehrke et al. Diabetes mellitus and heart failure
Horinaka Use of nicorandil in cardiovascular disease and its optimization
Kim et al. Efficacy of veno-arterial extracorporeal membrane oxygenation in acute myocardial infarction with cardiogenic shock
Sankaranarayanan et al. How does chronic atrial fibrillation influence mortality in the modern treatment era?
Mitsuhashi et al. Effect of losartan on ambulatory short-term blood pressure variability and cardiovascular remodeling in hypertensive patients on hemodialysis
NO20081196L (no) Terapeutisk middel for diabetes
De Caterina et al. Why β-blockers should not be used as first choice in uncomplicated hypertension
Chua et al. Renal dysfunction and the risk of postoperative atrial fibrillation after cardiac surgery: role beyond the CHA2DS2-VASc score
JOP20210039B1 (ar) مركبات بيريدين 6،2 - ديامينو
WO2018182051A8 (en) IP6K INHIBITORS
IL164774A0 (en) Use of valsartan or its metabolite to inhibit platelet aggregation
WO2006110887A3 (en) Use of glp-1, exendin and agonists thereof to delay or prevent cardiac remodeling
Kiviniemi et al. Exercise capacity and heart rate responses to exercise as predictors of short-term outcome among patients with stable coronary artery disease
De Caterina et al. The role of beta-blockers as first-line therapy in hypertension
RU2011138955A (ru) Производные 1, 4-бензотиазепин-1-оксида и фармацевтическая композиция с использованием таких соединений
Aoun et al. Beta-blockers use from the general to the hemodialysis population
Valentijn et al. Influence of aortic valve calcium on outcome in patients undergoing peripheral vascular surgery
Sadeghian et al. Two ecstasy-induced myocardial infarctions during a three month period in a young man
Güvenç et al. A novel explanation for the cause of atrial fibrillation seen in atherosclerotic coronary artery disease:“downstream inflammation” hypothesis
Özbiçer et al. Chronic statin treatment is a predictor of pre-interventional infarct-related artery patency in patients with ST elevation myocardial infarction treated with percutaneous coronary intervention
Aronow Editorials Editorial on management of diabetes mellitus with coronary artery disease
Rosano Cardiovascular pharmacotherapy a growing sub-speciality across all areas of cardiology: a European tradition
Biviano et al. The use of ranolazine in the management of recurrent atrial fibrillation after percutaneous radiofrequency ablation
Holczer et al. A Comprehensive Review of Acute Coronary Syndrome and Bypass Surgery: Recent Advances, Timing, and Indicative Considerations

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application